Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Opioid Overdose
Interventions
Observation only
Other
Lead sponsor
Member Companies of the Opioid PMR Consortium
Industry
Eligibility
18 Years to 79 Years
Enrollment
808,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Wilmington, Delaware • Boston, Massachusetts • Portland, Oregon + 1 more
Conditions
Post Operative Pain, Opioid Use, Unspecified
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
Placebo, Oxycodone + Naltrexone, Oxycodone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Hepatitis C
Interventions
Data-assisted Case Navigation, Standard of Care
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Healthy
Interventions
ALKS 5461, Buprenorphine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Conditions
Hepatitis C, Opiate Dependence
Interventions
Hepatitis C educational video
Procedure
Lead sponsor
Organization to Achieve Solutions in Substance Abuse (OASIS)
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Oakland, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Clinical Decision Support, Buprenorphine, Opioid-use Disorder
Interventions
Clinical Decision Support (CDS)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Gardendale, Alabama • Aurora, Colorado + 17 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

NCT05587998
Conditions
Opioid Use Disorder
Interventions
Morphine, AZD4041, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Abuse Potential
Interventions
Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg, pregabalin 450 mg with oxycodone 20 mg, oxycodone 20 mg, Placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Marlton, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers Results available

Parenting Young Children Study

NCT05180487
Conditions
Parenting, Parent-Child Relations, Opioid Misuse, Opioid Use Disorder, Stress, Depression, Parenting Self-efficacy
Interventions
Family Check-Up
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Lubiprostone, Naloxegol
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
34,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
Cocaine Dependence, Cocaine Use Disorder, Opiate Dependence, Opioid-use Disorder, Cannabis Dependence
Interventions
Four-Session Mind Freedom Plan, Treatment as usual therapy
Behavioral
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Terminated Phase 2 Interventional Results available

KAP for Depression in Abstinent Opioid Users

NCT05193318
Conditions
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
Interventions
Ketamine-assisted psychotherapy
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Not applicable Interventional Results available

Effective Treatment of Hepatitis C in Substance Users

NCT00633243
Conditions
Hepatitis C, Opiate Dependence
Interventions
Modified Directly Observed Therapy (mDOT), Self-Administered Therapy (SAT)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424
Conditions
Opioid Use Disorder
Interventions
Morphine Sulfate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Opioid Use Disorder, Alcohol Use Disorder
Interventions
Extended Release Naltrexone, Treatment As usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pain, Opioid Use
Interventions
PainTracker, Current Opioid Misuse Measure
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
65 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Nicotine Use Disoder, Opioid Use Disorder
Interventions
Sweet-cooling, Sweet non-cooling EC flavor, Tobacco flavor EC
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Conditions
Opioid-Related Disorders
Interventions
Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah